- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04140123
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
October 8, 2021 updated by: Guangdong Raynovent Biotech Co., Ltd
A Multi-center, Randomized, Double-blind, Dose-increasing, Placebo-controlled,Multi-dose, 28-day Continuous Administration Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, Efficacy, and PK of ZSP1601 in Patients With Nonalcoholic Steatohepatitis
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects are required to meet the following criteria in order to be included in the trial:
- Signature signed informed consent before the trial, and fully understood the content, process and possible adverse reactions.
- Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
- Subjects(including partners)have no gestation plans and must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.
- Male and female subjects aged 18-65 (including 18 and 65).
- B ultrasound confirmed fatty liver.
- NASH diagnosis or NASH phenotypic diagnosis.
- Liver fat ≥10% at baseline (MRI-PDFF)
Exclusion Criteria:
Eligible subjects must not meet any of the following exclusion criteria:
- Excessive drinking for 3 consecutive months within 1 year before screening.
- Allergic constitution.
- Subjects who donated blood or bleeding profusely(> 400 mL)in the 3 months preceding study screening.
- Subjects having a history of bariatric surgery or preparing for bariatric surgery recently.
- Subjects having a history of liver transplantation or plans for liver transplantation
- Any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers.
- Liver biopsy indicates cirrhosis or previous clinical diagnosis of cirrhosis.
- Type 1 diabetes mellitus.
- Uncontrolled type 2 diabetes mellitus (HbA1c≥8.0%)。
- Any clinically significant abnormality upon physical examination or in the clinical laboratory tests, history or presence of other causes of liver disease,but not limited to above disorders: hepatitis b or hepatitis c virus (HCV) infection and chronic alcoholic liver disease, drug-induced liver disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson 's disease, alpha 1 - antitrypsin deficiency, liver, obvious abnormal liver function (ALT and AST acuity 5 x ULN or TBIL acuity 1.5 x ULN), etc.
- Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.
- History of having any special food(including dragon fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 2 weeks prior to screening.
- Participated in another clinical research study and received any investigational products within 3 months prior to dosing.
- Presence of clinically significant abnormalities in ECG or QTcB>450ms in males,or QTcB>470ms in females.
- HIV positive.
- Clinically significant nephropathy or renal dysfunction, blood creatinine >1.5×ULN, eGFR< 60 mL/min/1.73m2 [calculation formula: Ccr:(140-age)× weight (kg) /0.818×Scr(mumol /L), female ×0.85].
- Platelet count <100×109/L.
- Antinuclear antibody (ANA) confirmed positive and clinically significant.
- Abnormal TSH with clinical significance.
- Female during pregnancy and lactation or positive serum pregnancy test.
- Patients with contraindication of MRI scan.
- Take any product contains alcohol within 24 hours prior to dosing.
- Have chocolate, any food or beverage that contains caffeine or xanthine within 24 hours prior to dosing.
- Positive for urine drug screening or history of substance abuse for a period of 5 consecutive years before screening.
- Any acute illness or concomitant medication from screening to first dosing.
- As judged by the researcher, it is not suitable to join the clinical researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Subjects will receive matching placebo of ZSP1601
|
Experimental: ZSP1601-Dose 1
ZSP1601-50mg once daily
|
ZSP1601 tablets be taken orally for 28 days.
Subjects will receive matching placebo of ZSP1601
|
Experimental: ZSP1601-Dose 2
ZSP1601-50mg twice daily
|
ZSP1601 tablets be taken orally for 28 days.
Subjects will receive matching placebo of ZSP1601
|
Experimental: ZSP1601-Dose 3
ZSP1601-100mg once daily
|
ZSP1601 tablets be taken orally for 28 days.
Subjects will receive matching placebo of ZSP1601
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses of ZSP1601 and placebo.
Time Frame: Initiation of study treatment (Day 1) up to 2 weeks post-treatment.
|
severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)
|
Initiation of study treatment (Day 1) up to 2 weeks post-treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI-PDFF
Time Frame: Baseline and Day 28.
|
liver fat content with Magnetic resonance imaging proton density fat fraction (MRI-PDFF)
|
Baseline and Day 28.
|
TNF-α
Time Frame: Baseline and Day 28.
|
Tumor necrosis factor alpha level in serum
|
Baseline and Day 28.
|
ALT
Time Frame: Baseline and Day 28.
|
serum Alanine Aminotransferase
|
Baseline and Day 28.
|
AST
Time Frame: Baseline and Day 28.
|
serum Aspartate Aminotransferase
|
Baseline and Day 28.
|
Tmax
Time Frame: Day1 and day 14
|
The time after dosing when Cmax occurs (Tmax)
|
Day1 and day 14
|
Cmax
Time Frame: Day1 and day 14
|
Maximum Contentration
|
Day1 and day 14
|
t1/2z
Time Frame: Day1 and day 14
|
t1/2z is defined as the time to decline half of the drug concentration in plasma.
|
Day1 and day 14
|
Rac of Cmax
Time Frame: Day1 and day 14
|
Rac of ZSP1601 Peak Plasma Concentration at steady state
|
Day1 and day 14
|
DF of ZSP1601 at steady status
Time Frame: Day1 and day 14
|
Multiple-dose plasma PK parameter: DF of ZSP1601 at steady status
|
Day1 and day 14
|
AUClast(AUC0-t)
Time Frame: Baseline (0h) and day 14
|
AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.
|
Baseline (0h) and day 14
|
Rac of AUC
Time Frame: Day1 and day 14
|
RAC of ZSP1601 Area under the plasma concentration versus time curve at steady state
|
Day1 and day 14
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC(inf)
Time Frame: Day1 and day 14
|
Area under the curve extrapolated until time is infinity (AUCinf)
|
Day1 and day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 23, 2020
Primary Completion (Actual)
August 3, 2021
Study Completion (Actual)
August 3, 2021
Study Registration Dates
First Submitted
October 15, 2019
First Submitted That Met QC Criteria
October 23, 2019
First Posted (Actual)
October 25, 2019
Study Record Updates
Last Update Posted (Actual)
October 11, 2021
Last Update Submitted That Met QC Criteria
October 8, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZSP1601-18-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Alcoholic Steatohepatitis (NASH)
-
Corcept TherapeuticsRecruitingNon-alcoholic Steatohepatitis (NASH)United States
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis (NASH)Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
-
Immuron Ltd.CompletedNon-alcoholic Steatohepatitis (NASH)United States, Australia, Israel
-
EccogeneRecruiting
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis NASHUnited Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
-
Hoffmann-La RocheCompletedNon-Alcoholic Steatohepatitis (NASH)France
-
University of ZurichCompletedNon-alcoholic Steatohepatitis (NASH)Switzerland
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-Alcoholic Steatohepatitis (NASH)China
-
AstraZenecaActive, not recruitingNon-alcoholic Steatohepatitis (NASH)United States
-
Zhejiang Medicine Co., Ltd.The Affiliated Hospital of Hangzhou Normal University; R&G Pharma Studies Co...CompletedNASH (Non-Alcoholic Steatohepatitis)China
Clinical Trials on ZSP1601
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.CompletedNonalcoholic Steatohepatitis (NASH)China
-
Guangdong Raynovent Biotech Co., LtdRecruitingNonalcoholic Steatohepatitis (NASH)China